Liquidia (NASDAQ:LQDA) Director Raman Singh Sells 8,468 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Raman Singh sold 8,468 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $66.16, for a total transaction of $560,242.88. Following the sale, the director owned 44,637 shares of the company’s stock, valued at approximately $2,953,183.92. The trade was a 15.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Raman Singh also recently made the following trade(s):

• On Friday, September 11th, Raman Singh sold 9,024 shares of Liquidia stock. The shares were sold at an average price of $68.62, for a total value of $619,226.88.

Liquidia Stock Performance

NASDAQ LQDA traded up $0.41 on Tuesday, hitting $65.72. 1,372,017 shares of the stock traded hands, compared to its average volume of 1,724,839. The business’s fifty day moving average is $77.19 and its two-hundred day moving average is $59.67. Liquidia Corporation has a 12 month low of $21.15 and a 12 month high of $93.61. The firm has a market capitalization of $5.88 billion, a price-to-earnings ratio of 47.97 and a beta of 0.53. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The firm had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The business’s quarterly revenue was up 1842.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.49) earnings per share. As a group, equities analysts anticipate that Liquidia Corporation will post 2.57 EPS for the current fiscal year.

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently bought and sold shares of the company. WINTON GROUP Ltd bought a new position in Liquidia in the 2nd quarter valued at $335,000. Arizona State Retirement System raised its position in shares of Liquidia by 5.4% in the second quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock worth $1,405,000 after buying an additional 900 shares in the last quarter. Nykredit A S bought a new stake in Liquidia during the second quarter valued at $177,000. Corient Private Wealth LP bought a new stake in Liquidia during the second quarter valued at $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Liquidia during the second quarter worth about $1,236,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on LQDA. Lifesci Capital cut Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research note on Wednesday, August 12th. Stephens set a $130.00 target price on shares of Liquidia in a research report on Friday, July 24th. Piper Sandler set a $129.00 target price on shares of Liquidia in a research note on Friday, July 24th. Raymond James Financial reissued a “strong-buy” rating and issued a $106.00 price target on shares of Liquidia in a research report on Thursday, August 13th. Finally, Wells Fargo & Company raised their price objective on shares of Liquidia from $62.00 to $108.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $98.08.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious cardiopulmonary conditions, including pulmonary arterial hypertension (PAH). The company is headquartered in Research Triangle Park, North Carolina, and serves healthcare providers and patients primarily in the United States.

Liquidia’s lead product is Yutrepia, an inhaled formulation of treprostinil designed for the treatment of PAH. The company has also developed treprostinil injection products and is pursuing additional therapies for rare cardiopulmonary diseases.